Lymphoma drug tested for rare scleroderma
NCT ID NCT03222492
First seen May 06, 2026 · Last updated May 06, 2026
Summary
This study tested a drug called brentuximab vedotin, already used for lymphoma, in 17 people with a severe form of scleroderma (diffuse cutaneous systemic sclerosis). The main goal was to check the drug's safety and find the right dose. It was an early step to see if targeting certain immune cells could help manage this disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLERODERMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Medical Center: Division of Rheumatology and Immunology
Durham, North Carolina, 27710, United States
-
Georgetown University Medical Center: Division of Rheumatology
Washington D.C., District of Columbia, 20057, United States
-
Hospital for Special Surgery, New York: Division of Rheumatology
New York, New York, 10021, United States
-
Medical University of South Carolina: Division of Rheumatology & Immunology
Charleston, South Carolina, 29425, United States
-
UCLA Medical Center: Division of Rheumatology
Los Angeles, California, 90095, United States
-
University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology
Ann Arbor, Michigan, 48109, United States
-
University of Pittsburgh Medical Center: Division of Rheumatology and Clinical
Pittsburgh, Pennsylvania, 15217, United States
-
University of Texas Houston Medical School: Division of Rheumatology and Clinical Immunogenetics
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.